Drug Trial Radar · NCT01543178
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
Last checked: Nov 20, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,583
Actual
Start
Feb 2012
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
Conditions
- Irritable Bowel Syndrome With Diarrhea
Interventions
open-label rifaximinDrug
550 mg three times a day (open-label)
double-blind placeboDrug
3 times a day (double-blind)
double-blind rifaximinDrug
550 mg three times a day (double-blind)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Repeat Treatment RespondersTime frame: 4-week treatment-free follow-up in double-blind repeat treatment phase.
Locations
296 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Anniston, Alabama
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Dothan, Alabama
Site not named
Huntsville, Alabama
Site not named
Montgomery, Alabama
Site not named
Montgomery, Alabama
Site not named
Selma, Alabama
Site not named
Chandler, Arizona
Site not named
Peoria, Arizona
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Jonesboro, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Little Rock, Arkansas
Site not named
North Little Rock, Arkansas
Site not named
Sherwood, Arkansas
Site not named
Anaheim, California
Site not named
Artesia, California
Site not named
Carlsbad, California
Site not named
Chula Vista, California
Site not named
Chula Vista, California
Site not named
Concord, California
Site not named
Encinitas, California
Site not named
Encino, California
Site not named
Escondido, California
Site not named
Garden Grove, California
Site not named
Garden Grove, California
Site not named
Garden Grove, California
Site not named
Glendale, California
Site not named
Huntington Beach, California
Site not named
La Mesa, California
Site not named
La Mirada, California
Showing 40 of 296 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.